GENE ONLINE|News &
Opinion
Blog

2020-03-25| Asia-PacificCOVID-19

Pharma Firm AnGes and Osaka University to Initiate Coronavirus Vaccine Testing on Animals

by GeneOnline
Share To

On March 24, 2020, AnGes, Inc, a Japanese biopharmaceutical company, announced that it had completed the development of a DNA vaccine against COVID-19 with Osaka University and it would start testing the vaccine on animals as early as this fall. Without the use of any pathogens, DNA vaccines have advantages such as safety and short production time over conventional attenuated vaccines.

The announcement spiked the shares of AnGes by as much as 17% in the morning trade in Tokyo on March 24, in comparison to a gain of 5.3% in the broader market.

AnGes is a drug-discovery company spun out of Osaka University. Their collaboration on a coronavirus vaccine was announced on March 5. Utilizing DAICEL Corp’s gene-transfer technology, Takara Bio Inc. is in charge of the vaccine production. As the technology facilitates efficient delivery of plasmid DNA encoding antigen protein into the cells, which ensures antibody production. As a result, a highly efficient vaccination can be achieved.

Pharmaceutical companies around the world are rushing to develop vaccines and treatments for coronavirus, which has reached 420,000 cases globally and resulted in over 18,000 deaths. In the meantime, in Japan, leading drugmaker Takeda Pharmaceutical Co. is in the development of a plasma-derived therapy, while the active ingredient in Fujifilm Holdings Corp’s Avigan anti-flu drug is being tested as a treatment in China.

Related Article: Purine Repressing Probiotic Might Halt COVID-19, says Korean Researchers

References
  1. https://geneonline.news/index.php/2020/03/25/dna-vaccine-anges-osaka-university-coronavirus/?doing_wp_cron=1585115776.7173950672149658203125
  2. https://www.reuters.com/article/us-health-coronavirus-japan-anges/pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals-idUSKBN21B019

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Ascletis Cleared By FDA To Begin Trial On Monkeypox Antiviral
2022-11-16
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!